|  
  |  
  |  
  |  
  |  
  |  
  |  
  |  
18 April 2014, Friday
 
 
Today's Zaman
 
 
 
 

Amgen to buy Turkish pharmaceutical firm MN for $670 mln

26 April 2012, Thursday /TODAY'S ZAMAN
The world's largest biotechnology company, Amgen, based in Thousand Oaks, California, is to acquire 95.6 percent of the shares in Mustafa Nevzat Pharmaceuticals (MN) for almost $670 million, the American firm said on Wednesday.

“The all-cash transaction will significantly expand Amgen's presence in Turkey and the surrounding region, which are large, fast-growing, priority markets for Amgen,” it said in a written statement. “Together with MN's staff and management team, we plan to grow our business with high-quality and innovative medicines in Turkey and the surrounding region,” Robert A. Bradway, president and chief operating officer at Amgen, was quoted as saying in the statement.

Established nearly 90 years ago, MN is the leading supplier of pharmaceuticals to the hospital sector and a major supplier of injectable medicines in Turkey. It also has a successful and fast-growing export business. In 2011, MN's revenue was approximately $200 million and has grown on average at double-digit rates in local currency over the past five years. "This transaction represents an attractive opportunity for MN, its employees and customers," said Levent Selamoğlu, general manager of MN. "The combination of MN and Amgen creates an innovation leader in Turkey with unique capabilities and scope to expand regionally and in other attractive, high-growth markets. Amgen's focus and resources will also ensure continued investment in Turkey,” he added.

The transaction has been approved by the boards of directors of both companies. Completion of the transaction is subject to the customary closing conditions, including regulatory approval.

Amgen's focus on Turkey and the surrounding region is part of a broad international expansion strategy for the company, the statement said. Amgen established an affiliate in Turkey two years ago and currently markets two products, with others already in the pipeline, ready to be developed for the benefit of patients in the country.

 
 
BUSINESS  Other Titles
Central bank head denies reports that he resigned
Turkey signs FTA with Malaysia, looks to boost trade volume
Tough year ahead for Turkish banks, Fitch says
Competition Authority investigation of THY to resume soon
Cut off from the world, Gazans consumed by poverty
Galatasaray to pay $35 mln in tax penalty
EU agrees to Putin's call for gas security talks
Twitter: No current deal to open office in Turkey
Ankara says Russia's South Stream pipeline could run to Turkey
Turkish central bank meeting eyed for signs of political meddling
Turkish cement firms eye assets after Holcim-Lafarge merger
CHP raises issue of irregularity in loans for Sabah-ATV sale
TUSKON key in trade with Turkey, top Russian group says
Number of job seekers hits 10-year high
Gül attends event of group labeled ‘traitors' by Erdoğan
'Banning social media disaster for any government's global image'
Pakistan publishes list to embarrass tax cheats into paying up
Turkish schools help to enhance trade relations with Africa
Unemployment rate sees decrease year-on-year in Jan
Pegasus Airlines to start flights to Bahrain
...
Bloggers